Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 2,301–2,400 of 2,656
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
Pal, A., & Sadhukhan, S. (2026) · Cureus · doi:10.7759/cureus.107542
“The observations from large clinical trials such as DAPA-CKD and EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) have demonstrated the potential of SGLT2i in managing CKD, even in the absence of diabetes [10, 6].”
Noninsulin Medications for Type 2 Diabetes
CASTRO-REVOREDO, I. A., & WEBSTER, S. C. M. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.12.006
Becerra, A. J. B., Garcia, M. C., Germán, J. B., Rodríguez-López, C., Otero, J. M. R., Chapel, J. A. E., Roca, L. N., Urquía, M. T., Lázaro, A. M. P., & Tuñón, J. (2026) · Biomedicines · doi:10.3390/biomedicines14050980
Tantush, A., Hamida, B. B., Sagher, M., Afsheen, N., Sager, M., Abusbaeh, A., Tantoush, M., Abusbaeh, A., Najaim, A., Alhamadi, M., et al. (2026) · Cureus · doi:10.7759/cureus.107653 · Cited by 1
“Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated robust renoprotective effects across the spectrum of chronic kidney disease (CKD) in large-scale trials, including DAPA-CKD and EMPA-KIDNEY [4,5].”
Talyshinskii, A., Gauhar, V., Yuen, S. K. K., Güven, S., Tokas, T., Tsaturyan, A., Enikeev, D. V., & Somani, B. K. (2026) · Asian journal of urology · doi:10.1016/j.ajur.2025.11.004
“…in Chronic Kidney Disease) and EMPA-KIDNEY (Study of Heart and Kidney Protection with Empa-gliflozin) trials involving IgA nephropathy, ischemic kidney disease, and hypertensive kidney disease, significant improvements in the progression of CKD were found even among non-diabetic patients [39 — 41].”
Fardin, A., Gholami, E., Maleki, M., Parsaei, H., & Yaribeygi, H. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05147-8
Wen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
“Renal-focused trials like DAPA-CKD (dapagliflozin, 2020) and EMPA-KIDNEY (empagliflozin, 2021) showed 39% and 30% renal composite reductions (HR 0.61 and 0.70), effective even at low eGFR (down to 20–25 mL/ min) [62, 63].”
InfluentialHierarchical composite endpoints for CKD trials
Zoccali, C. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag094
Wang, C.-A., Wang, W.-J., Chen, J., Jiang, Z.-H., & Wu, V. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113277 · Cited by 1
Prevalence of Hyperkalemia in a Contemporary European Cohort According to EKFC eGFR Categories
Villalvazo, P., Molinero, L.-M., Sánchez-Niño, M. D., & Ortíz, A. (2026) · Diagnostics · doi:10.3390/diagnostics16091309 · Cited by 1
Spanish Registry of Dialysis and Transplantation: 2023 Report and evolutive analysis
Quiroga, B., Mahíllo, B., Mazuecos, A., Ortiz, A., Troya, M. I., Hernández-Marrero, D., Alemán, S. T., Santiuste, C., Arévalo, O. L. R., Marqués-Vidas, M., et al. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501510 · Cited by 2
Lin, S., Chen, J., Hsiao, C.-C., Fang, Y., Chen, M., Tsai, M., & Yang, H. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70276 · Cited by 1
Abnormal lipid metabolism in senescent renal tubular cells in diabetic nephropathy
Wan, J., Shen, Y., Yang, X., Chen, J., Chen, K., Chen, K., & Chen, J. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06199-w · Cited by 2
New Insights Into Delaying Renal Progression: Cardiovascular, Renal & Metabolic Medicine
Daoud, R. M., Spencer, S., Desborough, R., & Bhandari, S. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53144 · Cited by 1
The effects of new antidiabetic drugs on the course of peripheral arterial occlusive disease
Kröger, K., Böhner, H., Behrendt, C., & von Beckerath, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0055
kansu, A., sengul, E., & ÇİFTLİK, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9215986/v1
Tsai, Y., Lai, T., Sung, C., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.04.130
Phongphithakchai, A., Klangbud, W. K., Srithongkul, T., Raksasuk, S., & Chatatikun, M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1812783
“However, when interpreted specifically for IgAN, randomized evidence remains constrained by subgroup sample sizes, variability in endpoint definitions, and limited reporting of IgAN-specific granular outcomes (10, 11, 16).”
Tănăsescu, M., Rosu, A.-M., Mincă, A., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026) · Life · doi:10.3390/life16050756 · Cited by 1
Zaihan, A. F., Hafiz, N. A. H. M., Hazamy, N. I. A. K., Termizy, A. Z., Roslan, N. I., Ganesan, P. M., Choe, S. H., & Kow, C. S. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01675-2
Jhu, J., Fang, Y.-W., Lin, Y. C., Liou, H., Chen, M., Tan, H.-R., & Tsai, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-49221-8 · Cited by 1
“SGLT2i has emerged as a promising treatment option for patients with advanced CKD, conferring considerable renal and cardiovascular benefits regardless of T2DM status in two randomized trials of DAPA-CKD and EMPA-CKD 8,9 .”
Dao, T., Lung, W.-C., Yang, Y.-Z., Chu, W., Tsan, Y., Chen, H.-Y., Chen, P., & Ho, W. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113282
Dattani, R., Purssell, N., Desilva, R., et al. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag144
Immunofluorescence Patterns in IgAN are Associated With Active, Necrotizing Lesions
Abou-Watfa, A. A., Scurt, F. G., Bender, S. T., Wiech, T., Gröne, H., & Mertens, P. R. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106568
“9 16-19 Here, we hypothesize that distinct immunological endotypes of IgAN exist, differing in their clinical and pathological characteristics.”
Die Bedeutung von SGLT2-Hemmern in der Urologie
Schwinger, M. (2026) · Uro-News · doi:10.1007/s00092-026-6967-z
Saleem, T., Rasool, M. F., Saeed, H., & Alqahtani, F. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2668704
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Padda, B., Kelleher, J. T., Muroke, V., Sridhar, V. S., Tremblay‐Gravel, M., Tardif, J., & Boulet, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1809193
David-Neto, E., David, A. E. R., Alves, B., Reusing, J. O., Lembe, C., Galante, N. Z., Silva, R., de Souza, P. S., Nakamura, M., & Junior, H. T. S. (2026) · Transplantation · doi:10.1097/tp.0000000000005741
Wu, X.-Y., & Zheng, B.-Q. (2026) · Research Square · doi:10.21203/rs.3.rs-9562745/v1
Portolés, J. M., Coll, E., Puchades, M. J., Broseta, J. J., Quiroga, B., Rodríguez, D., Bajo, M. A., Merino, J. L., Ojeda, R., de Sequera, P., et al. (2026) · Nefrología · doi:10.1016/j.nefro.2026.501576
Yang, Q., Jia, Y., Li, Z., Yu, Y., & Dang, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1781810
Emerging Cardiorenal Protective Therapies in Lupus Nephritis
Capón, I. M., Sandino, J., Galindo, M., & Morales, E. (2026) · Drugs · doi:10.1007/s40265-026-02337-7 · Cited by 2
Kidney Function and Mortality in Mexico: Prospective Study of 130,000 Adults
Aguilar-Ramirez, D. J., Tapia‐Conyer, R., Herrington, W. G., Ramírez-Reyes, R., Garcilazo‐Ávila, A., González-Carballo, C., Santacruz-Benítez, R., Bello‐Chavolla, O. Y., Bragg, F., Friedrichs, L. G., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101398
Dissecting out the unexpected effects of SGLT2 inhibitors on human aging
Katsuumi, G., & Minamino, T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag207 · Cited by 1
Effect of dapagliflozin in liver transplant recipients with chronic kidney disease
Graf, C., Zeuzem, N., Bauschen, A., Allgeier, J., Denk, G., Paulig, C., Kemmner, S., Guba, M. O., & Lange, C. M. (2026) · Journal of Liver Transplantation · doi:10.1016/j.liver.2026.100356
Targeting hypertension with SGLT2 inhibition: the EU-funded SGLT2 HYPE trial
Eitel, I., Saraei, R., & Rawish, E. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag301
Wang, F., Shen, C., Guo, W., Wang, J., Xie, J., Shen, G., & Lin, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s601248
Cardiorenal Effects of SGLT2 Inhibitors: A Meta-Analysis of Randomized Controlled Trials
Fall, M., Maimouna, T., Aïdara, S., Boubacar, B., Absatou, D. N., Moussa, D., Faye, D., & Amadou, M. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i5.7782 · Cited by 1
“In EMPA-KIDNEY, the effect was strongest in patients with UACR >300 mg/g (OR = 0.67; 95% CI: 0.58 – 0.78), compared with lower UACR groups 26 .”
InfluentialHyperglycemia following pancreas transplantation: Rethinking graft function and metabolic control
Singh, N., Parajuli, S., Rao, S., Alhamad, T., Niederhaus, S. V., Nieves‐Rivera, F., Diab, A., Stumpf, M. M., Albritton, M., Singh, A., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.05.714
Therapeutic Adjustments in Cardiorenal Syndrome: An Integrated Approach to Heart and Kidney Care
Bhattarai, S., Shah, B., Lerma, E. V., & Shah, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_16
Hypertension as a Link Between Renal and Cardiac Dysfunction
Yağmur, F. H., & Kanbay, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_5
Chronic Kidney Disease in Cardiovascular Pathologies
Obrișcă, B., & Ismail, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_4
Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan
Tomishima, H., Odawara, M., Hatta, T., et al. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02883-0
Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease
Pestka, D. L., Murphy, D. P., Kaplan, A. N., Taylor, B. C., Huynh, P., Rechtzigel, J. A., Kjos, S., Ellich, L. M., Atwood, M. A., Polsfuss, B. A., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.13081 · Cited by 2
Aoki, R., Matsuzaki, K., Suzuki, H., et al. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02881-2
Murtafa, K. M., Khanday, S. S., Srinivasan, R. V., Majeed, M. W., Arumapperuma, H. A., Anilkumar, A., Mohammed, S., Arshad, M. R., Chishti, M. L., & Andrabi, S. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05209-x · Cited by 1
Nastase, I., Iordachi, T. F. D., Gurzun, M., Guțu, C., & Sârbu, N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103909 · Cited by 1
Nakagawa, Y., Koizumi, M., Shimamura, N., et al. (2026) · CEN Case Reports · doi:10.1007/s13730-026-01130-5
“Sodium-glucose co-transporter-2 inhibitors may also be considered as a potential option because they have been shown to slow the decline of kidney function and reduce albumin-uria in CKD patients with proteinuria [36, 37].”
Glomerular frontiers: consensus perspectives from GlomCon Hawaii 2025
Ebrahimi, N., Mehr, A. P., Selvaskandan, H., Seethapathy, H. S., Obaidi, Z., Arora, S., Wieglay, N., Rajasekaran, A., Singh, T., Almutar, S. S., et al. (2026) · Rare Kidney Diseases · doi:10.1007/s44531-026-00002-6
Rapport 26-05. Dépistage, prévention et prise en charge de la maladie rénale chronique
Massy, Z. A., Ronco, P. M., & Ardaillou, R. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.05.011
Indicaciones de los fármacos iSGLT2
Llover, M. N., Jiménez, M. C., & Ruíz, Y. O. (2026) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2025.11.009
Anton, I. C., Solcan, C., Mititelu-Tarțău, L., Amălinei, C., Poroch, M., Poroch, V., Bucă, B. R., Tartau, C. G., Pelin, A.-M., & Botnariu, G. E. (2026) · Life · doi:10.3390/life16050793 · Cited by 1
“Similarly, the EMPA-KIDNEY study reported substantial protection against renal function decline in patients treated with EMPA [14].”
Tran, J.-C., Tian, Z., Willerding, J. M., Casper, J., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. M. W. (2026) · medRxiv · doi:10.64898/2026.05.22.26353858
Duan, Z.-Y., Gao, Y., Huang, M., Liang, Y., Hao, J., Wang, J., & Cai, G. (2026) · Life · doi:10.3390/life16060865
“Sodium–glucose cotransporter-2 inhibitors (SGLT2i) reduce renal endpoints and proteinuria when added to RASI, but uniformly cause an acute eGFR decline within 2 weeks to 2 months of initiation [7–9].”
Schäfer, A.-K. C., Pieper, D., Bayram, B., Ajrab, J., Delistefani, F., Zeisberg, M., Koziolek, M. J., & Wallbach, M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101416
Han, X.-Y., Li, Z.-Y., Chen, S.-F., Zhao, M. H., Little, M. A., & Chen, M. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001137
Islam, M. M., & Okere, A. N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113346
Umanath, K., Dwyer, J. P., & Mentz, R. J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1845339
Yang, J., Chen, Z., Han, H., Li, C., & Yue, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1834859
Yeh, S.-E., Lin, H., Lai, W., & Lin, H.-M. (2026) · Frontiers in Medicine · doi:10.64898/2026.05.28.26353938
Crepaldi, M. C., Vedovato, M., Morieri, M. L., Basso, G., Stefanelli, L. F., Alessi, M., Fioretto, P., & Fadini, G. P. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01885-1
Handelsman, Y., Cheng, A. Y. Y., Fadini, G. P., Kushner, P. R., Bonnet, F., Fioretto, P., KADOWAKI, T., Kanumilli, N., Cos, X., Frese, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03618-z
“This is likely due to the more established CKD-specific evidence base available for SGLT2is [10–12], and the fact that FLOW evaluated semaglutide in patients receiving prior guideline-directed standard of care, limiting generalisability to GLP-1 RAs more broadly as a first-line therapy [8, 9].”
Bravo, W. C. (2026) · Pediatrics in Review · doi:10.1542/pir.2025-006891
Elenjickal, E. J., Baroz, F., Boileau, P., Tsoukas, M. A., Sharma, A., & Mavrakanas, T. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70886
Corrêa, L. M. D. A., Silva, Y. R. D., Zanella, J., & de Santana, G. C. (2026) · Journal of Human Hypertension · doi:10.1038/s41371-026-01163-4
Zhang, R.-R., Huang, S., 王新杰, & Li, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1793030
Li, X., Yao, G., Wang, H., Zhao, T., Sun, Y., Gao, Q., Li, Z., & Chen, B. (2026) · PeerJ · doi:10.7717/peerj.21321 · Cited by 1
Matsushita, T., Wada, Y., Saburi, M., Kobayashi, K., Tsukamoto, S., Kawanami, D., Suzuki, D., Tsuriya, D., Wakui, H., Kanasaki, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02695-5
Brandts, J. (2026) · CardioVasc · doi:10.1007/s15027-026-4016-1
“SGLT2‑ Inhi‑ bitoren verzögern den Nierenfunkt‑ ionsverlust und senken die Hospitali‑ sierungsrate wegen Herzinsuffizienz über das gesamte Ejektionsfraktions‑ spektrum, ebenfalls unabhängig vom Glukosestoffwechsel [16, 17, 18, 19, 20].”
Atif, K., Atif, E., Ali, M., Hassan, M. A., Das, V., Ahmad, A., Fatima, K., Mukhlis, M., Ahmad, D., Zahid, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9817293/v1
Hughes, M. S., & Pasquel, F. J. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.015
Shi, Y.-H., Zhang, T.-J., He, F., & Guo-Bin, K. (2026) · World Journal of Diabetes · doi:10.4239/wjd.117740
Keskindağ, B., Blakeman, T., Hughes, A., Bell, S., Melvin, M., Nakamaru, F., Gray, M., Jani, B., Mackenzie, M., Scholes-Robertson, N. J., et al. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05084-9 · Cited by 1
Butler, J., Jamil, A., Cherney, D. Z. I., Jafar, T. H., Testani, J. M., & Khan, M. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag426 · Cited by 1
Eller, K., Koller, T., Buchta, C., Exner, M., Greiner, G., Griesmacher, A., Hellbert, K., Karimi, V., Cj, M., Säemann, M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02749-1
Andersen, C. F., Larsen, J. H., Omar, M., Nouhravesh, N., Kistorp, C., Tuxen, C., Knop, F. K., Forman, J. L., Davidovski, F. S., Køber, L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03216-x
Almadani, A. K., HORMAZ, D., Aljubori, H. M., Ayache, R. A., Ewaida, A. A., Ghosn, M., Hadari, A. A., Khater, E., Kidder, D., Al‐Salam, S., et al. (2026) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2026.176014
Dunn, J. M., Sammons, S. R., Umanath, K., & Dwyer, J. P. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01376-5
“Lastly, in EMPA-KIDNEY [23 ], CKD participants with eGFR as low as 20 mL/min/1.73 m^2 were randomized to either 10 mg empagliflozin or placebo.”
InfluentialKent, P. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch14
Pharmakotherapie der chronischen Herzinsuffizienz
Oexner, R. R., & Frantz, S. (2026) · Kardiologie up2date · doi:10.1055/a-2701-0826
Kim, H. (2026) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2026.24.e6
McGill, J. B., Green, J., Heerspink, H. J. L., Mann, J. F. E., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., Nangaku, M., BRINKER, M. D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70949
“Similarly, in the DAPA-CKD and EMPA-KIDNEY studies in patients with CKD, the effects of dapagliflozin and empagli-flozin on the composite outcomes of eGFR decline, ESKD or kidney or CV death were consistent in people with or without diabetes [35, 36].”
Nagahiro, T., Konishi, M., Kanaoka, T., Wakui, H., Yano, Y., Nagasu, H., Kishi, S., Nangaku, M., Hirakawa, Y., Nakagawa, N., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113377
Hinton, W., Joy, M., Forbes, A., Whyte, M., Ordóñez-Mena, J. M., Fan, X., Ferreira, F., Meza-Torres, B., Munro, N. M., de Lusignan, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70946
Cardio–kidney–metabolic syndrome: Underutilized screening and management in primary care settings
Zayan, T. A., & Khafagy, H. A. (2026) · World Advances in Renal Medicine · doi:10.25259/warm_24_2025
Wanigatunga, M., Holliday, M. W., & Navaneethan, S. D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001205
彭卫华, Shang, X., Zhang, C., & Liu, M. H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1849205 · Cited by 1
“The DAPA-CKD and EMPA-KIDNEY trials expanded the inclusion criteria to patients with eGFR down to 25 and 20 mL/ min/1.73 m 2 , respectively (16, 20).”
Influential麦, 麦. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662319
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
Choker, A. H. (2026) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70142 · Cited by 1
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Renal aging and associated diseases: Common mechanisms and therapeutic approaches
Muhammad, J. A., Julianto, N. M., Setiawan, T., Fadjaray, T. F., Elbert, F., Hussain, M., Wirawan, L. M., Jeong, D., & Kwon, H. Y. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100148 · Cited by 1
Chiang, P., Chen, S. C., & Hung, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9573853/v1
de Sá, J. R. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-e008pt
Tóth, B., Dobi, D., Kardos, M., & Pethő, Á. G. (2026) · Medicine · doi:10.1097/md.0000000000049225
de Sá, J. R. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-e008en
“This represents a critical missed opportunity, particularly in the current therapeutic landscape, in which GLP-1 receptor agonists 5 , sodium-glucose cotransporter-2 inhibitors (SGLT2i) 6–8 , and finerenone 9 have demonstrated consistent renoprotective benefits.”
Bellos, I., Marinaki, S., & Benetou, V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124840
Yalçın, Z. Ö., Erdut, A., Haberal, G., et al. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688512
“…have demonstrated that SGlt2i including cana-gliflozin, empagliflozin, dapagliflozin, and ertugliflozin can significantly slow the progression of CKd in both diabetic and non-diabetic patients, highlighting their therapeutic potential beyond glucose lowering in the nephrology care settings [5–7].”
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.